Wall Street analysts expect Synlogic Inc (NASDAQ:SYBX) to announce $650,000.00 in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Synlogic’s earnings, with estimates ranging from $300,000.00 to $1.60 million. Synlogic reported sales of $110,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 490.9%. The firm is expected to report its next quarterly earnings report on Tuesday, March 10th.
According to Zacks, analysts expect that Synlogic will report full year sales of $1.52 million for the current financial year, with estimates ranging from $1.00 million to $2.59 million. For the next financial year, analysts anticipate that the firm will post sales of $1.49 million, with estimates ranging from $1.20 million to $2.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Synlogic.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.09. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.46 million. Synlogic had a negative return on equity of 36.32% and a negative net margin of 4,574.82%.
SYBX has been the subject of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $20.00 target price on shares of Synlogic in a research report on Friday, August 9th. Chardan Capital reaffirmed a “buy” rating on shares of Synlogic in a research report on Thursday, September 19th. ValuEngine raised Synlogic from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Citigroup lowered Synlogic from a “buy” rating to a “sell” rating and decreased their target price for the company from $20.00 to $2.00 in a research report on Wednesday, August 21st. Finally, Oppenheimer lowered Synlogic from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Synlogic presently has an average rating of “Buy” and an average target price of $13.69.
Shares of NASDAQ SYBX opened at $2.10 on Friday. The company has a quick ratio of 14.43, a current ratio of 14.43 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $5.31. The firm has a market cap of $70.42 million, a PE ratio of -1.03 and a beta of 2.56. Synlogic has a twelve month low of $1.96 and a twelve month high of $11.43.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC bought a new position in shares of Synlogic in the 3rd quarter worth $34,000. Parametric Portfolio Associates LLC bought a new position in shares of Synlogic in the 2nd quarter worth $195,000. Charles Schwab Investment Management Inc. raised its position in shares of Synlogic by 11.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 3,708 shares in the last quarter. Northern Trust Corp raised its position in shares of Synlogic by 17.1% in the 2nd quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock worth $1,835,000 after acquiring an additional 29,401 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Synlogic by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 770,641 shares of the biotechnology company’s stock worth $7,013,000 after acquiring an additional 2,558 shares in the last quarter. 64.98% of the stock is owned by hedge funds and other institutional investors.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Featured Article: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.